SANTA CRUZ BIOTECHNOLOGY, INC.

TF (TF9-10H10): sc-80952



BACKGROUND

Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (prothrombin and factors X, IX, V and VIII), which are involved in a blood coagulation cascade leading to the formation of insoluble fibrin clots and the promotion of platelet aggregation. Coagulation factor V (factor V, FV, proaccelerin, labile factor) is a 2,196 amino acid, single chain glycoprotein that is cleaved by Thrombin to yield an active, Ca²⁺-dependent dimer that is essential to the blood coagulation cascade. Together with catalytic factor Xa and Ca²⁺ on the surface of platelets or endothelial cells, factor Va coordinates into a prothrombin. Tissue factor (TF), also designated coagulation Factor III, is a cell surface glycoprotein that enables cells to initiate blood coagulation cascades. It functions as a high-affinity receptor for coagulation Factor VII.

REFERENCES

- Davie, E.W., et al. 1975. Basic mechanisms in blood coagulation. Annu. Rev. Biochem. 44: 799-829.
- Kane, W.H., et al. 1986. Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin. Proc. Natl. Acad. Sci. USA 83: 6800-6804.
- Jenny, R.J., et al. 1987. Complete cDNA and derived amino acid sequence of human factor V. Proc. Natl. Acad. Sci. USA 84: 4846-4850.
- Davie, E.W., et al. 1991. The coagulation cascade: initiation, maintenance and regulation. Biochemistry 30: 10363-10370.
- Rand, M.D., et al. 1994. Platelet coagulation factor Va: the major secretory platelet phosphoprotein. Blood 83: 2180-2190.

CHROMOSOMAL LOCATION

Genetic locus: F3 (human) mapping to 1p21.3.

SOURCE

TF (TF9-10H10) is a mouse monoclonal antibody raised against TF of human origin.

PRODUCT

Each vial contains 100 μg lgG_1 in 1.0 ml of PBS with < 0.1% sodium azide, 1% gelatin and protein stabilizer.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

APPLICATIONS

TF (TF9-10H10) is recommended for detection of TF of human and primates origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 μ g per 1 x 10⁶ cells).

Suitable for use as control antibody for TF siRNA (h): sc-44984, TF shRNA Plasmid (h): sc-44984-SH and TF shRNA (h) Lentiviral Particles: sc-44984-V.

Molecular Weight of TF: 47 kDa.

Positive Controls: JEG-3 whole cell lysate: sc-364255.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-mouse IgG-HRP: sc-2005 (dilution range: 1:2000-1:32,000) or Cruz Marker[™] compatible goat anti-mouse IgG-HRP: sc-2031 (dilution range: 1:2000-1:5000), Cruz Marker[™] Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use goat anti-mouse IgG-FITC: sc-2010 (dilution range: 1:100-1:400) or goat anti-mouse IgG-TR: sc-2781 (dilution range: 1:100-1:400) with UltraCruz[™] Mounting Medium: sc-24941. 4) Immuno-histochemistry: use ImmunoCruz[™]: sc-2050 or ABC: sc-2017 mouse IgG Staining Systems.



132 К — 90 К —			
55 K – 43 K –	=]tf	
34 K –			
23 K –			

TF (TF9-10H10): sc-80952. Western blot analysis of TF expression in JEG-3 whole cell lysate.

SELECT PRODUCT CITATIONS

- Roberts, G.T., et al. 2008. Microvascular injury, thrombosis, inflammation, and apoptosis in the pathogenesis of heatstroke: a study in baboon model. Arterioscler. Thromb. Vasc. Biol. 28: 1130-1136.
- Xu, C., et al. 2011. Small interference RNA targeting tissue factor inhibits human lung adenocarcinoma growth *in vitro* and *in vivo*. J. Exp. Clin. Cancer Res. 30: 63.
- Peng, W., et al. 2013. The effects of small interfering RNA-targeting tissue factor on an *in vitro* model of neovascularization. Mol. Vis. 19: 1296-1303.